These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 24055993)
21. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Howard K; Barratt A; Mann GJ; Patel MI Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966 [TBL] [Abstract][Full Text] [Related]
23. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796 [TBL] [Abstract][Full Text] [Related]
24. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. Culp S; Porter M BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868 [TBL] [Abstract][Full Text] [Related]
25. The impact of informed consent on patient interest in prostate-specific antigen screening. Wolf AM; Nasser JF; Wolf AM; Schorling JB Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843 [TBL] [Abstract][Full Text] [Related]
26. [Early detection of prostate cancer by PSA testing: the results of a qualitative study on barriers caused by physicians in Austria implementing informed decision making]. Malli G Gesundheitswesen; 2013 Jan; 75(1):22-8. PubMed ID: 22836936 [TBL] [Abstract][Full Text] [Related]
27. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269 [TBL] [Abstract][Full Text] [Related]
28. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective. Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103 [TBL] [Abstract][Full Text] [Related]
29. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739 [TBL] [Abstract][Full Text] [Related]
30. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer. Hayat Roshanai A; Nordin K; Berglund G Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929 [TBL] [Abstract][Full Text] [Related]
31. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128 [TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Jønler M; Eddy B; Poulsen J Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092 [TBL] [Abstract][Full Text] [Related]
33. The patient perspective on a first raised PSA test. Brown C; Hodgson F; Obertova Z; Holmes M; Lawrenson R J Prim Health Care; 2015 Sep; 7(3):213-20. PubMed ID: 26437045 [TBL] [Abstract][Full Text] [Related]
34. Screening for prostate cancer: a survey of New Zealand general practitioners. Durham J; Low M; McLeod D N Z Med J; 2003 Jun; 116(1176):U476. PubMed ID: 12835804 [TBL] [Abstract][Full Text] [Related]
35. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594 [TBL] [Abstract][Full Text] [Related]
36. Attitudes and practices of primary care physicians for prostate cancer screening. Hoffman RM; Papenfuss MR; Buller DB; Moon TE Am J Prev Med; 1996; 12(4):277-81. PubMed ID: 8874692 [TBL] [Abstract][Full Text] [Related]
37. Falling through the cracks: New Zealand prostate cancer survivors' experiences and views regarding PSA testing. Patel A; MacLeod R; Masters J; Keogh J N Z Med J; 2014 Aug; 127(1400):106-9. PubMed ID: 25145373 [No Abstract] [Full Text] [Related]
38. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK. Brett J; Watson E; Hewitson P; Bukach C; Edwards A; Elwyn G; Austoker J BMC Fam Pract; 2005 Jun; 6(1):24. PubMed ID: 15946386 [TBL] [Abstract][Full Text] [Related]
39. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden. Pilebro B; Johansson R; Damber L; Damber JE; Stattin P Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278 [TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]